Correlation Between Mean Amplitude of Glycemic Excursion and Bone Turnover Markers in Patients with Type 2 Diabetes: A Cross-Sectional Study

References

• Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. 2011;305(21):2184–2192. doi:10.1001/jama.2011.715
   PubMed Web of Science ®Google Scholar
• Wang H, Ba Y, Xing Q, et al. Diabetes mellitus and the risk of fractures at specific sites: a meta-analysis. BMJ Open. 2019;9(1):e24067.
   PubMed Web of Science ®Google Scholar
• Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int. 2007;18(4):427–444. doi:10.1007/s00198-006-0253-4
   PubMed Web of Science ®Google Scholar
• Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495–505. doi:10.1093/aje/kwm106
   PubMed Web of Science ®Google Scholar
• Gregg EW, Beckles GL, Williamson DF, et al. Diabetes and physical disability among older U.S. adults. Diabetes Care. 2000;23(9):1272–1277. doi:10.2337/diacare.23.9.1272
   PubMed Web of Science ®Google Scholar
• Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study. J Clin Endocrinol Metab. 2006;91(9):3404–3410. doi:10.1210/jc.2006-0614
   PubMed Web of Science ®Google Scholar
• Manavalan JS, Cremers S, Dempster DW, et al. Circulating osteogenic precursor cells in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97(9):3240–3250. doi:10.1210/jc.2012-1546
   PubMed Web of Science ®Google Scholar
• Farr JN, Drake MT, Amin S, et al. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res. 2014;29(4):787–795. doi:10.1002/jbmr.2106
   PubMed Web of Science ®Google Scholar
• Tanaka K, Yamaguchi T, Kanazawa I, et al. Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells. Biochem Biophys Res Commun. 2015;461(2):193–199. doi:10.1016/j.bbrc.2015.02.091
   PubMed Web of Science ®Google Scholar
• Pacicca DM, Brown T, Watkins D, et al. Elevated glucose acts directly on osteocytes to increase sclerostin expression in diabetes. Sci Rep. 2019;9(1):17353. doi:10.1038/s41598-019-52224-3
   PubMed Web of Science ®Google Scholar
• Starup-Linde J, Lykkeboe S, Gregersen S, et al. Differences in biochemical bone markers by diabetes type and the impact of glucose. Bone. 2016;83:149–155. doi:10.1016/j.bone.2015.11.004
   PubMed Web of Science ®Google Scholar
• Xu F, Zhao LH, Su JB, et al. The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c. Diabetol Metab Syndr. 2014;6(1):139. doi:10.1186/1758-5996-6-139
   PubMedGoogle Scholar
• Starup-Linde J, Lykkeboe S, Handberg A, et al. Glucose variability and low bone turnover in people with type 2 diabetes. Bone. 2021;153:116159. doi:10.1016/j.bone.2021.116159
   PubMed Web of Science ®Google Scholar
• Noble JJ. Declaration of Helsinki. DEAD BMJ. 2007;335(7623):736.
   PubMedGoogle Scholar
• Draznin B, Aroda VR, Bakris G, et al. Summary of revisions: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Supplement_1):S4–S7.
   PubMedGoogle Scholar
• Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–254. doi:10.7326/0003-4819-145-4-200608150-00004
   PubMed Web of Science ®Google Scholar
• Monnier L, Colette C, Sardinoux M, et al. Frequency and severity of the Dawn phenomenon in type 2 diabetes: relationship to age. Diabetes Care. 2012;35(12):2597–2599. doi:10.2337/dc12-0385
   PubMed Web of Science ®Google Scholar
• Rausch JR. Measures of glycemic variability and links with psychological functioning. Curr Diab Rep. 2010;10(6):415–421. doi:10.1007/s11892-010-0152-0
   PubMed Web of Science ®Google Scholar
• Rong Huang HWZS. Increased glycemic variability evaluated by continuous glucose monitoring is associated with osteoporosis in type 2 diabetic patients. Front Endocrinol. 2022;13:861131.
   PubMed Web of Science ®Google Scholar
• Krege JH, Lane NE, Harris JM, et al. PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int. 2014;25(9):2159–2171. doi:10.1007/s00198-014-2646-0
   PubMed Web of Science ®Google Scholar
• Xu F, Ye YP, Dong YH, et al. Inhibitory effects of high glucose/insulin environment on osteoclast formation and resorption in vitro. J Huazhong Univ Sci Technol Med Sci. 2013;33(2):244–249. doi:10.1007/s11596-013-1105-z
   PubMedGoogle Scholar
• Levinger I, Seeman E, Jerums G, et al. Glucose-loading reduces bone remodeling in women and osteoblast function in vitro. Physiol Rep. 2016;4(3):e12700. doi:10.14814/phy2.12700
   PubMed Web of Science ®Google Scholar
• Tanaka KI. [ASBMR topics from clinical research(osteoporosis and sarcopenia).]. Clin Calcium. 2019;29(1):112–115. Japanese.
   PubMedGoogle Scholar
• Smith-Palmer J, Brandle M, Trevisan R, et al. Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(3):273–284. doi:10.1016/j.diabres.2014.06.007
   PubMed Web of Science ®Google Scholar
• Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010;12(4):288–298. doi:10.1111/j.1463-1326.2009.01160.x
   PubMed Web of Science ®Google Scholar
• Gorst C, Kwok CS, Aslam S, et al. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care. 2015;38(12):2354–2369. doi:10.2337/dc15-1188
   PubMed Web of Science ®Google Scholar
• Tanko LB, Christiansen C, Cox DA, et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res. 2005;20(11):1912–1920. doi:10.1359/JBMR.050711
   PubMed Web of Science ®Google Scholar
• Compston JE, Laskey MA, Croucher PI, et al. Effect of diet-induced weight loss on total body bone mass. Clin Sci. 1992;82(4):429–432. doi:10.1042/cs0820429
   Web of Science ®Google Scholar
• Andersen RE, Wadden TA, Herzog RJ. Changes in bone mineral content in obese dieting women. Metabolism. 1997;46(8):857–861. doi:10.1016/S0026-0495(97)90070-6
   PubMed Web of Science ®Google Scholar
• Jensen LB, Kollerup G, Quaade F, et al. Bone minerals changes in obese women during a moderate weight loss with and without calcium supplementation. J Bone Miner Res. 2001;16(1):141–147. doi:10.1359/jbmr.2001.16.1.141
   PubMed Web of Science ®Google Scholar
• Anhe FF, Barra NG, Schertzer JD. Glucose alters the symbiotic relationships between gut microbiota and host physiology. Am J Physiol Endocrinol Metab. 2020;318(2):E111–E116. doi:10.1152/ajpendo.00485.2019
   PubMed Web of Science ®Google Scholar
• Cheng B, Wen Y, Yang X, et al. Gut microbiota is associated with bone mineral density: an observational and genome-wide environmental interaction analysis in the UK Biobank cohort. Bone Joint Res. 2021;10(11):734–741. doi:10.1302/2046-3758.1011.BJR-2021-0181.R1
   PubMed Web of Science ®Google Scholar
• Qin Q, Yan S, Yang Y, et al. The relationship between osteoporosis and intestinal microbes in the Henan Province of China. Front Cell Dev Biol. 2021;9:752990. doi:10.3389/fcell.2021.752990
   PubMed Web of Science ®Google Scholar
• Liu R, Chao A, Wang K, et al. Incidence and risk factors of medical complications and direct medical costs after osteoporotic fracture among patients in China. Arch Osteoporos. 2018;13(1):12. doi:10.1007/s11657-018-0429-5
   PubMed Web of Science ®Google Scholar
• Domazetovic V, Fontani F, Marcucci G, et al. Estrogen inhibits starvation-induced apoptosis in osteocytes by a redox-independent process involving association of JNK and glutathione S-transferase P1-1. FEBS Open Bio. 2017;7(5):705–718. doi:10.1002/2211-5463.12216
   PubMed Web of Science ®Google Scholar
• Guo L, Chen K, Yuan J, et al. Estrogen inhibits osteoclasts formation and bone resorption via microRNA-27a targeting PPARgamma and APC. J Cell Physiol. 2018;234(1):581–594. doi:10.1002/jcp.26788
   PubMed Web of Science ®Google Scholar
• Chen Q, Kaji H, Sugimoto T, et al. Testosterone inhibits osteoclast formation stimulated by parathyroid hormone through androgen receptor. FEBS Lett. 2001;491(1–2):91–93. doi:10.1016/S0014-5793(01)02160-3
   PubMed Web of Science ®Google Scholar
• Rianon NJ, Smith SM, Lee M, et al. Glycemic control and bone turnover in older Mexican Americans with type 2 diabetes. J Osteoporos. 2018;2018:7153021. doi:10.1155/2018/7153021
   PubMed Web of Science ®Google Scholar
• Kulkarni SV, Meenatchi S, Reeta R, et al. Association of glycemic status with bone turnover markers in type 2 diabetes mellitus. Int J Appl Basic Med Res. 2017;7(4):247–251. doi:10.4103/ijabmr.IJABMR_35_17
   PubMedGoogle Scholar
• Colleluori G, Aguirre L, Dorin R, et al. Hypogonadal men with type 2 diabetes mellitus have smaller bone size and lower bone turnover. Bone. 2017;99:14–19. doi:10.1016/j.bone.2017.03.039
   PubMed Web of Science ®Google Scholar
• Thornton JD, Saunders R, Lian J, Karolicki B, Valentine W. The cost-effectiveness and budget impact of stepwise addition of bolus insulin in the treatment of type 2 diabetes: evaluation of the FullSTEP trial. J Med Econ. 2014;17(12):827–836. doi:10.3111/13696998.2014.959590
   PubMedGoogle Scholar